Angiotensin-converting enzyme 2 attenuates the metastasis of non-small cell lung cancer through inhibition of epithelial-mesenchymal transition

Qian,Yan-Rong; Guo,Yi; Wan,Huan-Ying; Fan,Liang; Feng,Yun; Ni,Lei; Xiang,Yi; Li,Qing-Yun

doi:10.3892/or.2013.2370

Angiotensin-converting enzyme 2 attenuates the metastasis of non-small cell lung cancer through inhibition of epithelial-mesenchymal transition

Authors:
- Yan-Rong Qian
- Yi Guo
- Huan-Ying Wan
- Liang Fan
- Yun Feng
- Lei Ni
- Yi Xiang
- Qing-Yun Li
View Affiliations

Affiliations: Respiratory Department, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200025, P.R. China
Published online on: March 29, 2013 https://doi.org/10.3892/or.2013.2370
Pages: 2408-2414

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Angiotensin-converting enzyme 2 (ACE2) is a key enzyme of the renin-angiotensin system (RAS). ACE2 plays a critical counterbalancing role by degrading angiotensin II (Ang II) to Ang 1-7. Recent studies suggest that RAS influences tumor growth and development by its paracrine effects on the tumor microenvironment. Epithelial‑mesenchymal transition (EMT) is now thought to be a process that plays a fundamental role in tumor progression and metastasis. In the present study, we investigated the role of ACE2 in lung cancer metastasis and the mechanism of EMT. This is the first study to elucidate the mechanism through which the overexpression of ACE2 in the A549 lung cancer cell line decreases metastasis formation in vivo and upregulates the expression of E-cadherin both in vitro and in vivo. We also observed the downregulation of vimentin, which supports a role of ACE2 in influencing EMT in lung cancer. Further analysis indicated that ACE2 abrogated the upregulation of TGF-β1-induced EMT markers, such as vimentin and α-smooth muscle actin (αSMA) in vitro in A549 cells. Finally, exposing A549 cells stably expressing ACE2 to DX600, an inhibitor of ACE2, recovered the sensitivity of lung cancer cells to TGF-β1-mediated induction of EMT. Our study demonstrated that ACE2 attenuated the metastasis of lung cancer and may serve as a target for new strategies to inhibit EMT in cancer cells.

View Figures

View References

1	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar
2	Thiery JP, Acloque H, Huang RY and Nieto MA: Epithelial-mesenchymal transitions in development and disease. Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
3	Zhou L, Zhang R, Zhang L, Yao W, Li J and Yuan Y: Angiotensin-converting enzyme 2 acts as a potential molecular target for pancreatic cancer therapy. Cancer Lett. 307:18–25. 2011. View Article : Google Scholar : PubMed/NCBI
4	Pickel L, Matsuzuka T, Doi C, Ayuzawa R, Maurya DK, Xie S-X, Berkland C and Tamura M: Overexpression of angiotensin II type 2 receptor gene induces cell death in lung adenocarcinoma cells. Cancer Biol Ther. 9:277–285. 2010. View Article : Google Scholar : PubMed/NCBI
5	George AJ, Thomas WG and Hannan RD: The renin-angiotensin system and cancer: old dog, new tricks. Nat Rev Cancer. 10:745–759. 2010.PubMed/NCBI
6	Wilop S, von Hobe S, Crysandt M, Esser A, Osieka R and Jost E: Impact of angiotensin I converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non-small-cell lung cancer undergoing first-line platinum-based chemotherapy. J Cancer Res Clin Oncol. 135:1429–1435. 2009. View Article : Google Scholar
7	Li H, Qi Y, Li C, Braseth LN, Gao Y, Shabashvili AE, Katovich MJ and Sumners C: Angiotensin type 2 receptor-mediated apoptosis of human prostate cancer cells. Mol Cancer Ther. 8:3255–3265. 2009. View Article : Google Scholar : PubMed/NCBI
8	Redondo-Müller MA, Stevanovic-Walker M, Barker S, Puddefoot JR and Vinson GP: Anti-cancer actions of a recombinant antibody (R6313/G2) against the angiotensin II AT1 receptor. Endocr Relat Cancer. 15:277–288. 2008.PubMed/NCBI
9	Nakai Y, Isayama H, Ijichi H, Sasaki T, Sasahira N, Hirano K, Kogure H, Kawakubo K, Yagioka H, Yashima Y, et al: Inhibition of renin-angiotensin system affects prognosis of advanced pancreatic cancer receiving gemcitabine. Br J Cancer. 103:1644–1648. 2010. View Article : Google Scholar : PubMed/NCBI
10	Feng Y, Ni L, Wan H, Fan L, Fei X, Ma Q, Gao B, Xiang Y, Che J and Li Q: Overexpression of ACE2 produces antitumor effects via inhibition of angiogenesis and tumor cell invasion in vivo and in vitro. Oncol Rep. 26:1157–1164. 2011.PubMed/NCBI
11	Okamoto K, Tajima H, Nakanuma S, Sakai S, Makino I, Kinoshita J, Hayashi H, Nakamura K, Oyama K, Nakagawara H, et al: Angiotensin II enhances epithelial-to-mesenchymal transition through the interaction between activated hepatic stellate cells and the stromal cell-derived factor-1/CXCR4 axis in intrahepatic cholangiocarcinoma. Int J Oncol. 41:573–582. 2012.
12	Feng Y, Wan H, Liu J, Zhang R, Ma Q, Han B, Xiang Y, Che J, Cao H, Fei X, et al: The angiotensin-converting enzyme 2 in tumor growth and tumor-associated angiogenesis in non-small cell lung cancer. Oncol Rep. 23:941–948. 2010.PubMed/NCBI
13	Ni L, Feng Y, Wan H, Ma Q, Fan L, Qian Y, Li Q, Xiang Y and Gao B: Angiotensin-(1–7) inhibits the migration and invasion of A549 human lung adenocarcinoma cells through inactivation of the PI3K/Akt and MAPK signaling pathways. Oncol Rep. 27:783–790. 2012.
14	Iwatsuki M, Mimori K, Yokobori T, Ishi H, Beppu T, Nakamori S, Baba H and Mori M: Epithelial-mesenchymal transition in cancer development and its clinical significance. Cancer Sci. 101:293–299. 2010. View Article : Google Scholar : PubMed/NCBI
15	Puddefoot JR, Udeozo UK, Barker S and Vinson GP: The role of angiotensin II in the regulation of breast cancer cell adhesion and invasion. Endocr Relat Cancer. 13:895–903. 2006. View Article : Google Scholar : PubMed/NCBI
16	Uemura H, Ishiguro H, Nagashima Y, Sasaki T, Nakaigawa N, Hasumi H, Kato S and Kubota Y: Antiproliferative activity of angiotensin II receptor blocker through cross-talk between stromal and epithelial prostate cancer cells. Mol Cancer Ther. 4:1699–1709. 2005. View Article : Google Scholar : PubMed/NCBI
17	Kanehira T, Tani T, Takagi T, Nakano Y, Howard EF and Tamura M: Angiotensin II type 2 receptor gene deficiency attenuates susceptibility to tobacco-specific nitrosamine-induced lung tumorigenesis: involvement of transforming growth factor-beta-dependent cell growth attenuation. Cancer Res. 65:7660–7665. 2005.
18	Tikellis C, Bernardi S and Burns WC: Angiotensin-converting enzyme 2 is a key modulator of the renin-angiotensin system in cardiovascular and renal disease. Curr Opin Nephrol Hypertens. 20:62–68. 2011. View Article : Google Scholar : PubMed/NCBI
19	Bangalore S, Kumar S, Kjeldsen SE, Makani H, Grossman E, Wetterslev J, Gupta AK, Sever PS, Gluud C and Messerli FH: Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324,168 participants from randomised trials. Lancet Oncol. 12:65–82. 2011. View Article : Google Scholar : PubMed/NCBI
20	Pasternak B, Svanström H, Callréus T, Melbye M and Hviid A: Use of angiotensin receptor blockers and the risk of cancer. Circulation. 123:1729–1736. 2011. View Article : Google Scholar : PubMed/NCBI
21	Chang CH, Lin JW, Wu LC and Lai MS: Angiotensin receptor blockade and risk of cancer in type 2 diabetes mellitus: a nationwide case-control study. J Clin Oncol. 29:3001–3007. 2011. View Article : Google Scholar : PubMed/NCBI
22	Bhaskaran K, Douglas I, Evans S, van Staa T and Smeeth L: Angiotensin receptor blockers and risk of cancer: cohort study among people receiving antihypertensive drugs in UK General Practice Research Database. BMJ. 344:e26972012. View Article : Google Scholar
23	Ferrario CM: ACE2: more of Ang-(1–7) or less Ang II? Curr Opin Nephrol Hypertens. 20:1–6. 2011.
24	Gembardt F, Sterner-Kock A, Imboden H, Spalteholz M, Reibitz F, Schultheiss HP, Siems WE and Walther T: Organ-specific distribution of ACE2 mRNA and correlating peptidase activity in rodents. Peptides. 26:1270–1277. 2005. View Article : Google Scholar : PubMed/NCBI
25	Shenoy V, Ferreira AJ, Qi Y, Fraga-Silva RA, Diez-Freire C, Dooies A, Jun JY, Sriramula S, Mariappan N, Pourang D, et al: The angiotensin-converting enzyme 2/angiogenesis-(1–7)/Mas axis confers cardiopulmonary protection against lung fibrosis and pulmonary hypertension. Am J Respir Crit Care Med. 182:1065–1072. 2010.
26	Hanahan D and Weinberg RA: Hallmarks of cancer: the next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
27	Moustakas A and Heldin CH: Induction of epithelial-mesenchymal transition by transforming growth factor β. Semin Cancer Biol. 22:446–454. 2012.
28	Perez RE, Navarro A, Rezaiekhaligh MH, Mabry SM and Ekekezie II: TRIP-1 regulates TGF-β1-induced epithelial-mesenchymal transition of human lung epithelial cell line A549. Am J Physiol Lung Cell Mol Physiol. 300:L799–L807. 2011.PubMed/NCBI
29	Arnold SA, Rivera LB, Carbon JG, Toombs JE, Chang CL, Bradshaw AD and Brekken RA: Losartan slows pancreatic tumor progression and extends survival of SPARC-null mice by abrogating aberrant TGFβ activation. PLoS One. 7:e313842012.PubMed/NCBI
30	Burns WC, Velkoska E, Dean R, Burrell LM and Thomas MC: Angiotensin II mediates epithelial-to-mesenchymal transformation in tubular cells by ANG 1-7/MAS-1-dependent pathways. Am J Physiol Renal Physiol. 299:F585–F593. 2010. View Article : Google Scholar : PubMed/NCBI
31	Rodrigues-Ferreira S, Abdelkarim M, Dillenburg-Pilla P, Luissint AC, di-Tommaso A, Deshayes F, Pontes CL, Molina A, Cagnard N, Letourneur F, et al: Angiotensin II facilitates breast cancer cell migration and metastasis. PLoS One. 7:e356672012. View Article : Google Scholar : PubMed/NCBI